ALKEM Stock Overview
A pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Alkem Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹5,406.30 |
| 52 Week High | ₹6,439.90 |
| 52 Week Low | ₹4,407.05 |
| Beta | 0.44 |
| 1 Month Change | -3.17% |
| 3 Month Change | -13.17% |
| 1 Year Change | 8.72% |
| 3 Year Change | 55.13% |
| 5 Year Change | 168.45% |
| Change since IPO | 291.28% |
Recent News & Updates
Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models
Nov 16
Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching
Nov 15Recent updates
Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models
Nov 16Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching
Nov 15What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You
Sep 24Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?
Sep 03Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 27Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00
Jul 13Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 27Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00
Jun 13Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Jun 01Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)
May 22Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets
Feb 13Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects
Jan 17We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease
Dec 27Shareholder Returns
| ALKEM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.3% | 0.6% | -4.2% |
| 1Y | 8.7% | 40.2% | 19.4% |
Return vs Industry: ALKEM underperformed the Indian Pharmaceuticals industry which returned 40.2% over the past year.
Return vs Market: ALKEM underperformed the Indian Market which returned 19.4% over the past year.
Price Volatility
| ALKEM volatility | |
|---|---|
| ALKEM Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: ALKEM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ALKEM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 17,432 | Vikas Gupta | www.alkemlabs.com |
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms.
Alkem Laboratories Limited Fundamentals Summary
| ALKEM fundamental statistics | |
|---|---|
| Market cap | ₹646.40b |
| Earnings (TTM) | ₹21.22b |
| Revenue (TTM) | ₹128.32b |
30.5x
P/E Ratio5.0x
P/S RatioIs ALKEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALKEM income statement (TTM) | |
|---|---|
| Revenue | ₹128.32b |
| Cost of Revenue | ₹48.19b |
| Gross Profit | ₹80.13b |
| Other Expenses | ₹58.90b |
| Earnings | ₹21.22b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 177.50 |
| Gross Margin | 62.44% |
| Net Profit Margin | 16.54% |
| Debt/Equity Ratio | 10.4% |
How did ALKEM perform over the long term?
See historical performance and comparisonDividends
0.7%
Current Dividend Yield3%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 02:18 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alkem Laboratories Limited is covered by 35 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Shrikant Akolkar | Angel Broking Private Limited |
| null null | Antique Stockbroking Ltd. |